A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA (original) (raw)

References

Brunak S, Engelbrecht J and Knudsen S . (1991). J. Mol. Biol., 220, 49–65.
Cox DG and Canzian F . (2001). Bioinformatics, 17, 738–739.
Dumont P, Leu JI, Della Pietra AC, George DL and Murphy M . (2003). Nat. Genet., 33, 357–365.
Excoffier L and Slatkin M . (1995). Mol. Biol. Evol., 12, 921–927.
Hebsgaard SM, Korning PG, Tolstrup N, Engelbrecht J, Rouze P and Brunak S . (1996). Nucleic Acids Res., 24, 3439–3452.
Landi S, Moreno V, Gioia-Patricola L, Guino E, Navarro M, de Oca J, Capella G and Canzian F . (2003). Cancer Res., 63, 3560–3566.
Lazar V, Hazard F, Bertin F, Janin N, Bellet D and Bressac B . (1993). Oncogene, 8, 1703–1705.
Powell BL, van Staveren IL, Roosken P, Grieu F, Berns EM and Iacopetta B . (2002). Carcinogenesis, 23, 311–315.
Rogan PK, Faux BM and Schneider TD . (1998). Hum. Mutat., 12, 153–171.
Runnebaum IB, Tong XW, Konig R, Zhao H, Korner K, Atkinson EN, Kreienberg R, Kieback DG, Hong Z and Zhao H . (1995). Lancet, 345, 994.
Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G and Banks L . (1998). Nature, 393, 229–234.
Tõnisson N, Zernant J, Kurg A, Pavel H, Slavin G, Roomere H, Meiel A, Hainaut P and Metspalu A . (2002). Proc. Natl. Acad. Sci. USA, 99, 5503–5508.
Wang-Gohrke S, Becher H, Kreienberg R, Runnebaum IB and Chang-Claude J . (2002). Pharmacogenetics, 12, 269–272.
Wang-Gohrke S, Weikel W, Risch H, Vesprini D, Abrahamson J, Lerman C, Godwin A, Moslehi R, Olipade O, Brunet JS, Stickeler E, Kieback DG, Kreienberg R, Weber B, Narod SA and Runnebaum IB . (1999). Br. J. Cancer, 81, 179–183.
Weston A, Pan CF, Ksieski HB, Wallenstein S, Berkowitz GS, Tartter PI, Bleiweiss IJ, Brower ST, Senie RT and Wolff MS . (1997). Cancer Epidemiol. Biomarkers Prev., 6, 105–112.
Wu X, Zhao H, Amos CI, Shete S, Makan N, Hong WK, Kadlubar FF and Spitz MR . (2002). J. Natl. Cancer Inst., 94, 681–690.

Download references